

# Expression Pathology

## Expression Pathology Aids Research in Identifying Biomarkers of Lung Cancer Metastasis and Survival

**Gaithersburg, MD, February 19, 2008** – Expression Pathology Inc. (EPI), a leader in tissue protein analysis, announced that researchers at Tokyo Medical University, using the company's tissue microproteomics technologies, identified protein biomarkers associated with lung cancer metastasis, which were further studied for correlation to clinical outcomes. The researchers used EPI's Liquid Tissue® reagents and Director™ laser microdissection slides to analyze formalin-fixed paraffin-embedded (FFPE) tissue samples by mass spectrometry.

“A novel combination of technologies has enabled proteomic discovery and analysis of previously unusable archived tissue, first in a semi-quantitative manner and then in a more targeted way to focus on specific individual proteins,” said Professor Toshihide Nishimura of Tokyo Medical University and a scientific advisor to EPI. “We were able to take the same Liquid Tissue processed samples used in discovery and measure the relative expression of candidate biomarkers with recent advances in Multiple Reaction Monitoring. We have demonstrated their utility as indicators of the stage of disease and predictors of patient survival.”

A white paper detailing the methodology and results of the research to date is available from Expression Pathology; for a complimentary download, visit [www.expressionpathology.com](http://www.expressionpathology.com).

“FFPE tissue archives represent an extraordinary resource for mining protein biomarkers associated with differential clinical outcomes,” said David Krizman, PhD, EPI's Chief Scientific Officer. “However, detailed proteomic analysis by mass spectrometry of specific cellular features of these samples has, until recently, not been feasible.”

“This study clearly demonstrates how Expression Pathology's Liquid Tissue MS Prep and Director slides have opened archived tissue to discovery and validation of protein biomarkers of differential pathologies and clinical outcomes,” Dr. Krizman continued.

### **About Expression Pathology Inc.**

Formalin-fixed and paraffin-embedded (FFPE) tissue samples are routinely collected and stored in medical treatment and research facilities. They constitute a huge untapped resource for discovery, validation and accurate measurement of biomarkers of disease progression and recurrence, drug response and toxicity. Expression Pathology's Liquid Tissue® reagents and Director™ laser microdissection slides are opening new ways to extract valuable protein information from FFPE tissue, and could provide the foundation for a new generation of clinical research and diagnostic tools. Please visit [www.expressionpathology.com](http://www.expressionpathology.com).

### **Contacts**

Expression Pathology

Peter Tunon

Vice President, Sales and Marketing

301-977-3654

[p.tunon@expressionpathology.com](mailto:p.tunon@expressionpathology.com)

[www.expressionpathology.com](http://www.expressionpathology.com)